JPWO2023194528A5 - - Google Patents
Info
- Publication number
- JPWO2023194528A5 JPWO2023194528A5 JP2024559034A JP2024559034A JPWO2023194528A5 JP WO2023194528 A5 JPWO2023194528 A5 JP WO2023194528A5 JP 2024559034 A JP2024559034 A JP 2024559034A JP 2024559034 A JP2024559034 A JP 2024559034A JP WO2023194528 A5 JPWO2023194528 A5 JP WO2023194528A5
- Authority
- JP
- Japan
- Prior art keywords
- azd5305
- pharmaceutically acceptable
- acceptable salt
- prostate cancer
- darolutamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263362612P | 2022-04-07 | 2022-04-07 | |
| US63/362,612 | 2022-04-07 | ||
| PCT/EP2023/059126 WO2023194528A1 (en) | 2022-04-07 | 2023-04-06 | Combination therapy for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025511401A JP2025511401A (ja) | 2025-04-15 |
| JPWO2023194528A5 true JPWO2023194528A5 (https=) | 2026-04-10 |
| JP2025511401A5 JP2025511401A5 (https=) | 2026-04-10 |
Family
ID=86185292
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024559034A Pending JP2025511401A (ja) | 2022-04-07 | 2023-04-06 | 癌を治療するための併用療法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250235448A1 (https=) |
| EP (1) | EP4504180A1 (https=) |
| JP (1) | JP2025511401A (https=) |
| KR (1) | KR20240170956A (https=) |
| CN (1) | CN118973572A (https=) |
| AU (1) | AU2023248685A1 (https=) |
| CA (1) | CA3254948A1 (https=) |
| IL (1) | IL316016A (https=) |
| MX (1) | MX2024012368A (https=) |
| TW (1) | TW202404593A (https=) |
| WO (1) | WO2023194528A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026021478A1 (zh) * | 2024-07-23 | 2026-01-29 | 江苏恒瑞医药股份有限公司 | Ar降解剂与parp1抑制剂联合用于治疗前列腺癌的方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0705903B2 (en) | 1994-08-12 | 2009-08-12 | The University of Utah Research Foundation | Mutations in the 17q-linked breast and ovarian cancer susceptibility gene |
| DK0699754T3 (da) | 1994-08-12 | 2001-02-26 | Myriad Genetics Inc | Fremgangsmåde til diagnosticering af prædisposition for bryst- og ovariecancer |
| AR078793A1 (es) | 2009-10-27 | 2011-12-07 | Orion Corp | Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros |
| MX2022000711A (es) | 2019-07-19 | 2022-02-23 | Astrazeneca Ab | Inhibidores de parp1. |
| TW202228693A (zh) * | 2020-10-08 | 2022-08-01 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合療法 |
-
2023
- 2023-04-06 WO PCT/EP2023/059126 patent/WO2023194528A1/en not_active Ceased
- 2023-04-06 US US18/853,491 patent/US20250235448A1/en active Pending
- 2023-04-06 AU AU2023248685A patent/AU2023248685A1/en active Pending
- 2023-04-06 KR KR1020247036943A patent/KR20240170956A/ko active Pending
- 2023-04-06 CN CN202380032429.6A patent/CN118973572A/zh active Pending
- 2023-04-06 CA CA3254948A patent/CA3254948A1/en active Pending
- 2023-04-06 JP JP2024559034A patent/JP2025511401A/ja active Pending
- 2023-04-06 EP EP23719307.3A patent/EP4504180A1/en active Pending
- 2023-04-06 IL IL316016A patent/IL316016A/en unknown
- 2023-04-07 TW TW112112999A patent/TW202404593A/zh unknown
-
2024
- 2024-10-04 MX MX2024012368A patent/MX2024012368A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023041862A5 (https=) | ||
| JP2024015120A5 (https=) | ||
| JP5890780B2 (ja) | 中枢を介する悪心および嘔吐を治療するための組成物および方法 | |
| JP2022180461A5 (https=) | ||
| TW201210593A (en) | Compositions and methods for treating centrally mediated nausea and vomiting | |
| RU2008142899A (ru) | Композиции далбаванцина для лечения бактериальных инфекций | |
| JP2020516646A5 (https=) | ||
| TWI441639B (zh) | 用於治療卵巢癌之包含紫杉醇之組合 | |
| RU2010109359A (ru) | Азитромицин для лечения кожных заболеваний | |
| JP2016505050A5 (https=) | ||
| JP2004525143A5 (https=) | ||
| WO2017148129A1 (zh) | 一种用于治疗恶病质的药物组合物及其应用 | |
| JP2022177119A5 (https=) | ||
| EP4494700A3 (en) | New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases | |
| TW200306185A (en) | Combinations comprising EPOTHILONES and anti-metabolites | |
| CN116113411A (zh) | 用于治疗软组织肉瘤的联用药物 | |
| JPWO2023194528A5 (https=) | ||
| JPWO2023194530A5 (https=) | ||
| CN103596565B (zh) | 塞克硝唑在口腔感染治疗中的应用 | |
| JPWO2023194525A5 (https=) | ||
| JP2012031141A (ja) | 骨髄異形性症候群を治療するための組成物および方法 | |
| JPWO2020157577A5 (https=) | ||
| WO2020207344A1 (zh) | 匹莫齐特和甲氨蝶呤的药物组合及其应用 | |
| CN1537006A (zh) | 含有米尔塔扎平和对乙酰氨基酚或一种非甾类消炎药的用于治疗头痛的联合用药物 | |
| JP2012025734A (ja) | 骨髄異形性症候群を治療するための組成物および方法 |